Richard M Bergenstal

Summary

Affiliation: International Diabetes Center
Country: USA

Publications

  1. doi request reprint Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Curr Med Res Opin 27:531-40. 2011
  2. ncbi request reprint The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Am J Med 118:1S-6S. 2005
  3. doi request reprint Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, MN, USA
    Am J Med 123:374.e 9 -18. 2010
  4. doi request reprint Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    N Engl J Med 363:311-20. 2010
  5. doi request reprint Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Lancet 376:431-9. 2010
  6. doi request reprint Threshold-based insulin-pump interruption for reduction of hypoglycemia
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    N Engl J Med 369:224-32. 2013
  7. pmc Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, 3800 Park Nicollet Blvd, Minneapolis, MN 55416 2699, USA
    J Diabetes Sci Technol 7:562-78. 2013
  8. doi request reprint Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Diabetes Technol Ther 15:198-211. 2013
  9. pmc Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
    R M Bergenstal
    International Diabetes Center, Minneapolis, MN, USA
    Diabetes Obes Metab 15:264-71. 2013
  10. ncbi request reprint Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota 55416, USA
    Diabetes Technol Ther 14:851-7. 2012

Detail Information

Publications32

  1. doi request reprint Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Curr Med Res Opin 27:531-40. 2011
    ..To describe the Exenatide Observational Study (ExOS) and patients initiating exenatide therapy in a real-world clinical practice setting...
  2. ncbi request reprint The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Am J Med 118:1S-6S. 2005
    ..A set of 16 consensus statements was approved by the panel. This article presents the 16 statements together with some brief rationale for their inclusion...
  3. doi request reprint Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, MN, USA
    Am J Med 123:374.e 9 -18. 2010
    ....
  4. doi request reprint Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    N Engl J Med 363:311-20. 2010
    ..Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors...
  5. doi request reprint Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Lancet 376:431-9. 2010
    ....
  6. doi request reprint Threshold-based insulin-pump interruption for reduction of hypoglycemia
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    N Engl J Med 369:224-32. 2013
    ..We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia...
  7. pmc Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, 3800 Park Nicollet Blvd, Minneapolis, MN 55416 2699, USA
    J Diabetes Sci Technol 7:562-78. 2013
    ....
  8. doi request reprint Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Diabetes Technol Ther 15:198-211. 2013
    ....
  9. pmc Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
    R M Bergenstal
    International Diabetes Center, Minneapolis, MN, USA
    Diabetes Obes Metab 15:264-71. 2013
    ..The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1 receptor agonist, on glycaemic control and CV risk factors...
  10. ncbi request reprint Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota 55416, USA
    Diabetes Technol Ther 14:851-7. 2012
    ..Conclusions: Study findings showed that advanced features of the CONTOUR BGMS increased structured testing as measured by postprandial and paired SMBG and were perceived as useful by patients...
  11. pmc Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)
    Richard M Bergenstal
    Park Nicollet International Diabetes Center, Minneapolis, MN, 55416, USA
    Diabetes Ther 3:13. 2012
    ..The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type 2 diabetes...
  12. doi request reprint Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Endocr Pract 18:371-5. 2012
    ..To evaluate treatment patterns associated with diabetes medication regimen changes after hospitalization on the basis on preadmission hemoglobin A1c levels...
  13. doi request reprint Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Curr Med Res Opin 27:2335-42. 2011
    ..The Exenatide BID Observational Study (ExOS) was designed to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes (T2D) in a real-world clinical practice setting in the United States...
  14. pmc A1C predicts type 2 diabetes and impaired glucose tolerance in a population at risk: the community diabetes prevention project
    Silmara Ao Leite
    Universidade Positivo, Curitiba, PR, Brazil
    Diabetol Metab Syndr 1:5. 2009
    ..In a population at risk for type 2 diabetes (T2DM), we assessed early physical and metabolic markers that predict progression from normal to impaired glucose tolerance (IGT) and T2DM...
  15. pmc Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker for insulin resistance
    Silmara Ao Leite
    Universidade Positivo, Curitiba, PR, Brasil
    Diabetol Metab Syndr 1:8. 2009
    ....
  16. pmc Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA
    Diabetes Care 34:2403-5. 2011
    ..05). CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months...
  17. pmc Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA
    Diabetes Care 31:1305-10. 2008
    ..We sought to compare an insulin-to-carbohydrate ratio with a simple algorithm for adjusting the dose of prandial insulin glusiline...
  18. ncbi request reprint Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Diabetes Technol Ther 7:241-7. 2005
    ..The Accu-Chek Acculink modem (Roche Diagnostics Corp., Indianapolis, IN) provides an additional and attractive option that can potentially facilitate this communication...
  19. pmc Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
    Aaron S Kelly
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA
    Cardiovasc Diabetol 11:64. 2012
    ..We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes...
  20. doi request reprint Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota, USA
    Diabetes Technol Ther 11:S45-52. 2009
    ..as compared with existing treatment options alone, leads to greater initiation and maintenance of insulin therapy and improves glycemic control in patients with type 2 diabetes...
  21. pmc Can a tool that automates insulin titration be a key to diabetes management?
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA
    Diabetes Technol Ther 14:675-82. 2012
    ..Ann Arbor, MI) software, which automatically advises patients on adjustment of insulin dosage, would provide safe and effective weekly insulin dosage adjustments...
  22. doi request reprint Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use
    David M Kendall
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota 55416, USA
    Am J Med 122:S37-50. 2009
    ....
  23. ncbi request reprint Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing
    Dawn M Bina
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Diabetes Care 26:981-5. 2003
    ....
  24. ncbi request reprint Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes
    Richard M Bergenstal
    International Diabetes Center, Park Nicollet Institute, Minneapolis, Minnesota, USA
    Endocr Pract 12:98-104. 2006
    ..To discuss treatment models used at the International Diabetes Center (IDC) and present strategies for transitioning patients with type 2 diabetes from orally administered medications to insulin therapy...
  25. ncbi request reprint Improving blood pressure control in individuals with diabetes: a quality improvement collaborative
    Margaret A Powers
    International Diabetes Center, Park Nicollet, Minneapolis, USA
    Jt Comm J Qual Patient Saf 37:110-9. 2011
    ..Methods to improve BP control are needed. A quality improvement (QI) collaborative was established to improve systolic BP (SBP) control in persons with diabetes...
  26. ncbi request reprint Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control
    Richard M Bergenstal
    International Diabetes Center, Minneapolis, Minnesota 55416, USA
    Endocr Pract 11:172-9. 2005
    ....
  27. pmc A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN, USA
    Diabetes Care 35:2140-7. 2012
    ..To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL)...
  28. doi request reprint Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use
    David M Kendall
    International Diabetes Center at Park Nicollet, Minneapolis, Minnesota 55416, USA
    Eur J Intern Med 20:S329-39. 2009
    ....
  29. doi request reprint A new look at screening and diagnosing diabetes mellitus
    Christopher D Saudek
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Clin Endocrinol Metab 93:2447-53. 2008
    ..This report reconsiders the criteria for diagnosing diabetes and recommends screening criteria to make case finding easier for clinicians and patients...
  30. doi request reprint Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis
    Leonard C Glass
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 24:639-44. 2008
    ..This analysis further characterizes the relative impact of commonly employed insulin analogues versus exenatide on weight change over a 6-month period...
  31. ncbi request reprint Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial
    Ralph A DeFronzo
    University of Texas Health Science Center, Diabetes Division, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
    Diabetes Care 28:1922-8. 2005
    ..This study investigates whether inhaled insulin (INH; Exubera) can achieve target glycemic control in patients failing on diet and exercise...
  32. doi request reprint Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM)
    Irl B Hirsch
    Department of Medicine, University of Washington Medical Center Roosevelt, Seattle, Washington 98105, USA
    Diabetes Technol Ther 10:232-44; quiz 245-6. 2008
    ..Finally, researchers, manufacturers, payers, and advocacy groups must join forces on the policy level to create an environment conducive to managing continuous data, measuring outcomes, and formalizing best practices...